DK1718756T3 - Botulinumtoksinscreeningassays - Google Patents

Botulinumtoksinscreeningassays

Info

Publication number
DK1718756T3
DK1718756T3 DK05724048.3T DK05724048T DK1718756T3 DK 1718756 T3 DK1718756 T3 DK 1718756T3 DK 05724048 T DK05724048 T DK 05724048T DK 1718756 T3 DK1718756 T3 DK 1718756T3
Authority
DK
Denmark
Prior art keywords
methods
bont
activity
botulinumtoksinscreeningassays
fgfr3
Prior art date
Application number
DK05724048.3T
Other languages
English (en)
Inventor
Ester Fernandez-Salas
Patton E Gary
Kei Roger Aoki
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1718756T3 publication Critical patent/DK1718756T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • External Artificial Organs (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
DK05724048.3T 2004-02-24 2005-02-23 Botulinumtoksinscreeningassays DK1718756T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54759104P 2004-02-24 2004-02-24
PCT/US2005/006421 WO2005082096A2 (en) 2004-02-24 2005-02-23 Botulinum toxin screening assays

Publications (1)

Publication Number Publication Date
DK1718756T3 true DK1718756T3 (da) 2012-02-27

Family

ID=34910920

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05724048.3T DK1718756T3 (da) 2004-02-24 2005-02-23 Botulinumtoksinscreeningassays

Country Status (9)

Country Link
US (3) US7598027B2 (da)
EP (1) EP1718756B1 (da)
JP (1) JP4970057B2 (da)
AT (1) ATE533853T1 (da)
AU (2) AU2005216547B2 (da)
CA (1) CA2558758C (da)
DK (1) DK1718756T3 (da)
ES (1) ES2374822T3 (da)
WO (1) WO2005082096A2 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022172B2 (en) * 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US7374896B2 (en) * 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US20080064054A1 (en) * 2001-08-28 2008-03-13 Ester Fernandez-Salas Fluorescence resonance energy transfer (fret) assays for clostridial toxin activity
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
DK1718756T3 (da) * 2004-02-24 2012-02-27 Allergan Inc Botulinumtoksinscreeningassays
US8497081B2 (en) * 2004-02-24 2013-07-30 Allergan, Inc. Botulinum toxin screening assays
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20080274480A1 (en) * 2004-08-04 2008-11-06 Allergan, Inc. Botulinum Toxin Type a Immunoresistant Assay
WO2006099590A2 (en) 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
ATE555387T1 (de) * 2005-10-12 2012-05-15 Allergan Inc Tests der molekularen oder subzellulären nähe unter verwendung von depolarisierung nach resonanzenergietransfer (daret)
EP2505592A1 (en) * 2006-07-11 2012-10-03 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
US8445650B2 (en) * 2007-09-25 2013-05-21 Thomas Jefferson University Mutant botulinum neurotoxin serotype A polypeptide and uses thereof
US8198034B2 (en) 2008-03-14 2012-06-12 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
KR101604515B1 (ko) * 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
RU2535003C2 (ru) 2008-12-10 2014-12-10 Аллерган, Инк. Фармацевтические композиции токсина клостридий
WO2010085473A1 (en) 2009-01-20 2010-07-29 Trustees Of Tufts College Methods for the delivery of toxins or enzymatically active portions thereof
WO2010105236A1 (en) 2009-03-13 2010-09-16 Allergan, Inc. Immuno-based retargeted endopeptidase activity assays
CN102439138B (zh) 2009-03-13 2018-03-30 阿勒根公司 可用于基于免疫的肉毒杆菌毒素血清a型活性测定的细胞
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
KR101640694B1 (ko) * 2011-09-29 2016-07-18 셀스냅, 엘엘씨 독소생산능 시험용 조성물 및 방법
EP2798077A2 (en) 2011-12-31 2014-11-05 Allergan, Inc. Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A
US20150153325A1 (en) * 2012-05-11 2015-06-04 Patrick McNutt Toxin detection using stem cell derived neurons
PT2854840T (pt) 2012-05-30 2018-03-02 Harvard College Neurotoxina botulínica geneticamente modificada
US8962340B2 (en) 2012-12-03 2015-02-24 Src, Inc. Real-time assay for the detection of botulinum toxin
AU2013373679A1 (en) 2013-01-16 2015-08-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) A soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
LT3270162T (lt) 2013-08-09 2020-09-10 Biomadison, Inc. Padidinto jautrumo botulino toksino tyrimas
EP3567055A1 (en) 2014-07-07 2019-11-13 Allergan, Inc. Method of detecting cleaved snap25 in tissue samples
HK1248737A1 (zh) 2015-03-26 2018-10-19 哈佛大学校长及研究员协会 工程改造的肉毒杆菌神经毒素
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
HUE058734T2 (hu) 2016-07-07 2022-09-28 Pfizer Szolúbilis 3-as fibroblaszt növekedési faktor receptor (sFGFR3) polipeptidek és alkalmazásaik
EP3504226A1 (en) 2016-08-24 2019-07-03 President and Fellows of Harvard College Engineered botulinum neurotoxin
IL265109B2 (en) 2016-09-13 2024-05-01 Allergan Inc Stabilized non-protein clostridial toxin compositions
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112020012641A2 (pt) 2017-12-20 2020-12-01 Allergan, Inc. polipeptídeos de domínio de ligação celular de toxina de botulinum e métodos de uso para rejuvenescimento da pele
KR101940500B1 (ko) * 2018-11-29 2019-01-21 주식회사 에이비바이오 보툴리눔 독소 활성을 결정하기 위한 세포주 및 이를 이용한 활성 결정 방법
EP3660509B1 (en) 2018-11-29 2022-03-09 Hugel Inc. A cell-based method for determining an activity of botulinum toxin
AR119109A1 (es) * 2019-06-07 2021-11-24 Synaptic Res Llc Células genéticamente manipuladas
JP2020015733A (ja) * 2019-08-19 2020-01-30 アンセルムＩｎｓｅｒｍ 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
BR112023002455A2 (pt) 2020-08-21 2023-03-28 Genzyme Corp Anticorpos fgfr3 e métodos de uso
EP4349992A4 (en) * 2021-05-24 2025-09-24 Atgc Co Ltd BOTULINUM TOXIN-SENSITIVE CELLS INTO WHICH A SPECIFIC GENE HAS BEEN INSERTED BY A LENTIVIRUS

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750365A (en) 1993-05-28 1998-05-12 The Ohio State University Research Foundation Isolated nucleic acid encoding a newt acidic fibroblast growth factor (AFGF)
US5962637A (en) * 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
US5731161A (en) * 1995-04-24 1998-03-24 Allergan, Inc. Botulinum toxin antibody detection assay
US5965699A (en) * 1996-11-06 1999-10-12 The United States Of America As Represented By The Secretary Of The Army Assay for the proteolytic activity of serotype a from clostridium botulinum
US7923015B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
US7923216B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
US6794128B2 (en) * 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
IL128380A0 (en) 1999-02-04 2000-01-31 Yeda Res & Dev A method of screening for agonists and antagonists of FGFR
CA2384294A1 (en) * 1999-09-15 2001-03-22 Janssen Pharmaceutica N.V. Nicotinic acetylcholine receptor: alpha10 subunit
US20030219462A1 (en) * 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US6913877B1 (en) * 2000-09-11 2005-07-05 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Methods for detecting bioactive compounds
IL138529A0 (en) * 2000-09-18 2003-09-17 Yeda Res & Dev High level expression of heterologous proteins
US7415358B2 (en) * 2001-05-22 2008-08-19 Ocimum Biosolutions, Inc. Molecular toxicology modeling
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20080064054A1 (en) * 2001-08-28 2008-03-13 Ester Fernandez-Salas Fluorescence resonance energy transfer (fret) assays for clostridial toxin activity
US7208285B2 (en) * 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US20070118934A1 (en) * 2001-10-26 2007-05-24 Planet Biotechnology, Inc. Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
WO2003083046A2 (en) * 2002-03-08 2003-10-09 Curagen Corporation Novel proteins and nucleic acids encoding same
IL149562A0 (en) * 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
NZ537120A (en) * 2002-05-31 2008-07-31 Univ Jefferson Compositions and methods for transepithelial molecular transport
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US7090985B2 (en) * 2002-12-03 2006-08-15 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
WO2004051222A2 (en) * 2002-12-03 2004-06-17 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
US20060153876A1 (en) * 2003-02-24 2006-07-13 Ira Sanders Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
WO2005054188A1 (en) * 2003-12-02 2005-06-16 Ucb, S.A. Imidazole derivatives, processes for preparing them and their uses
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
JP4656836B2 (ja) * 2003-12-19 2011-03-23 パナソニック株式会社 同期クロック生成装置及び同期クロック生成方法
DK1718756T3 (da) * 2004-02-24 2012-02-27 Allergan Inc Botulinumtoksinscreeningassays
WO2006012309A1 (en) * 2004-06-25 2006-02-02 Cold Spring Harbor Laboratory Inducible inactivation of synaptic transmission
ATE552500T1 (de) * 2005-04-05 2012-04-15 Allergan Inc Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität
EP1985276A1 (en) * 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy

Also Published As

Publication number Publication date
WO2005082096A3 (en) 2006-06-22
ES2374822T3 (es) 2012-02-22
JP2007526770A (ja) 2007-09-20
US7645570B2 (en) 2010-01-12
JP4970057B2 (ja) 2012-07-04
EP1718756A4 (en) 2008-06-04
AU2005216547B2 (en) 2009-03-12
AU2009202136A1 (en) 2009-06-18
US8257914B2 (en) 2012-09-04
CA2558758A1 (en) 2005-09-09
US7598027B2 (en) 2009-10-06
EP1718756A2 (en) 2006-11-08
AU2005216547A1 (en) 2005-09-09
AU2009202136B2 (en) 2011-12-22
WO2005082096A2 (en) 2005-09-09
US20080003240A1 (en) 2008-01-03
US20080182799A1 (en) 2008-07-31
US20090317839A1 (en) 2009-12-24
CA2558758C (en) 2015-06-23
EP1718756B1 (en) 2011-11-16
ATE533853T1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
ATE533853T1 (de) Botulinumtoxin-screening-assays
ATE490306T1 (de) Methoden zur medikamentenaufspürung auf der basis von in vitro differenzierten zellen
DE602005022704D1 (de) Sensor für mehrere analyte
EP1907001A4 (en) ILT3 BONDING MOLECULES AND ITS USES
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
ZA200802500B (en) Modified antigen binding molecules with altered cell signaling activity
EP2064345A4 (en) PSORASE-ASSOCIATED GENETIC POLYMORPHIA, PROOF METHOD AND ITS USE
NO20091064L (no) Antistoffer mot IL-17A
DE602005017876D1 (de) Brennstoffzellensystem und steuerverfahren dafür
DE602006013653D1 (de) System zum nachweis und zur analyse der ausbreitung biologischer abfallprodukte in unterwäsche
ATE511645T1 (de) Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme
EP2133342A4 (en) INHIBITOR OF PROTEINTHYROSINE PHOSPHATASE 1B, METHOD OF MANUFACTURE AND APPLICATIONS THEREOF
WO2008033427A3 (en) Compositions and methods for detection of lysosomal storage disease
WO2007103146A3 (en) Truncated proteins as cancer markers
ATE446509T1 (de) Serumfreie expansion von zellen in kultur
CY1112090T1 (el) Μεθοδος για ανιχνευση βιολογικων οργανισμων με χρηση σκεδασης raman
FR2901806B1 (fr) Dispositif et ensemble de controle microbiologique
WO2012024546A3 (en) Incorporation of health measurments in analysis and interpretation of functional biological response data
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
DE602005015559D1 (de) Pharmakodynamische tests mit durchflusszytometrie
ATE553386T1 (de) Bluttypisierung
EP1799840A4 (en) ILT3-POLYPEPTIDES AND USES THEREOF
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
ATE471147T1 (de) Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren
WO2007026355A3 (en) Modulators of cell migration and methods of identifying same